April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Outcomes of Persistently Active Neovascular Age-Related Macular Degeneration Treated with VEGF Inhibitors: Observational Study data
Author Affiliations & Notes
  • Daniel Barthelmes
    Ophthalmology, University Hospital Zurich, Zurich, Switzerland
    The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
  • Richard Walton
    The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
  • Judy M Simpson
    Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia
  • Jennifer Arnold
    Marsden Eye Specialists, Paramatta, NSW, Australia
  • Ian McAllister
    The Lions Eye Institute, Perth, WA, Australia
  • Robyn H Guymer
    Center for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia
  • Alex Paul Hunyor
    The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
    Retina Associates, Chatswood, NSW, Australia
  • Rohan W Essex
    Department of Ophthalmology, Canberra Hospital, Garran, ACT, Australia
  • Nigel Morlet
    Department of Population Health, University of Western Australia, Perth, WA, Australia
  • Mark C Gillies
    The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
  • Footnotes
    Commercial Relationships Daniel Barthelmes, None; Richard Walton, None; Judy Simpson, None; Jennifer Arnold, None; Ian McAllister, None; Robyn Guymer, None; Alex Hunyor, None; Rohan Essex, None; Nigel Morlet, None; Mark Gillies, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniel Barthelmes, Richard Walton, Judy M Simpson, Jennifer Arnold, Ian McAllister, Robyn H Guymer, Alex Paul Hunyor, Rohan W Essex, Nigel Morlet, Mark C Gillies; Outcomes of Persistently Active Neovascular Age-Related Macular Degeneration Treated with VEGF Inhibitors: Observational Study data. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To describe outcomes of eyes with wet AMD subdivided by lesion activity in a large multicenter cohort study.

Methods: Treatment-naïve eyes with sub-foveal choroidal neovascularization receiving anti-VEGF therapy enrolled in the Fight Retinal Blindness! observational study were included. Lesions were graded at each visit as active if there was intraretinal or subretinal fluid attributable to leak from CNV lesion, or fresh hemorrhage. Eyes were divided into 4 groups based the proportion of visits each eye was graded as active during the first 12 months of treatment (Persistent, High, Moderate and Low activity).

Results: 655 eyes were included. Low activity group (n=153) were graded active in 0-26% of visits, moderate activity group (n=154) were graded active during 27-57% of visits, high activity group (n=152) were graded active during 58-99% of visits and eyes in the persistent activity group (n=196) were graded active in 100% of visits. Similar mean visual acuity changes compared with baseline were observed in all 4 groups at 12 months (+6.8, +8.3, +6.2 and +5.5 letters for the Low, Moderate, High and Persistent groups respectively; p<0.001 for each group). The mean number of injections given increased only modestly in groups with more active lesions (7.6, 7.9, 8.4, 8.3 respectively, P=0.015). Proportions of occult and minimally classic lesions were higher in the more active groups (P=0.024).

Conclusions: Persistent activity of neovascular lesions during 12 months after starting intravitreal therapy was not associated with worse visual outcomes in this observational study of AMD.

Keywords: 412 age-related macular degeneration • 462 clinical (human) or epidemiologic studies: outcomes/complications • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×